All In Biotech

Drug Trial Radar · NCT00391027

A Clinical Trial Comparing the Efficacy and Safety of Exubera® and Lantus®

A Six Month, Open-Label Outpatient, Randomized Parallel Group Trial Assessing The Impact Of Dry Powder Inhaled Insulin (Exubera®) On Glycemic Control Compared To Insulin Glargine (Lantus®) In Patients With Type 2 Diabetes Mellitus Who Are Poorly Controlled On A Combination Of Two Or More Oral Agents

Last checked: Nov 20, 2026Latest source record: Aug 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 261 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

261

Actual

Start

Dec 2006

Primary completion

Aug 2008

Study completion Aug 2008

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Oct 23, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 30 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To compare efficacy and safety of Exubera® vs Lantus® in patients with type 2 diabetes mellitus.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

  • Insulin Glargine (Lantus®)Drug

    Patient will be randomized to Lantus® while remaining on pre-study oral hypoglycemic agents.

  • Inhaled Human Insulin (Exubera®)Drug

    Patient will be randomized inhaled insulin while remaining on pre-study oral hypoglycemic agents.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26Time frame: Baseline, Week 26

Locations

62 sites in 10 countries. Site status is shown where the registry gives one.

  • Pfizer Investigational Site

    Bornem, Belgium

  • Pfizer Investigational Site

    Brussels, Belgium

  • Pfizer Investigational Site

    Genk, Belgium

  • Pfizer Investigational Site

    Liège, Belgium

  • Pfizer Investigational Site

    Kuopio, Finland

  • Pfizer Investigational Site

    Lahti, Finland

  • Pfizer Investigational Site

    Oulu, Finland

  • Pfizer Investigational Site

    Besançon, France

  • Pfizer Investigational Site

    Corbeil-Essonnes, France

  • Pfizer Investigational Site

    La Rochelle, France

  • Pfizer Investigational Site

    Marseille, France

  • Pfizer Investigational Site

    Paris, France

  • Pfizer Investigational Site

    Valenciennes, France

  • Pfizer Investigational Site

    Altenburg, Germany

  • Pfizer Investigational Site

    Eisenach, Germany

  • Pfizer Investigational Site

    Hamburg, Germany

  • Pfizer Investigational Site

    Hohenmölsen, Germany

  • Pfizer Investigational Site

    Leipzig, Germany

  • Pfizer Investigational Site

    Neuss, Germany

  • Pfizer Investigational Site

    Riesa, Germany

  • Pfizer Investigational Site

    Wangen / Allgaeu, Germany

  • Pfizer Investigational Site

    's-Hertogenbosch, Netherlands

  • Pfizer Investigational Site

    Eindhoven, Netherlands

  • Pfizer Investigational Site

    Nijmegen, Netherlands

  • Pfizer Investigational Site

    The Hague, Netherlands

  • Pfizer Investigational Site

    Venlo, Netherlands

  • Pfizer Investigational Site

    Bergen, Norway

  • Pfizer Investigational Site

    Jessheim, Norway

  • Pfizer Investigational Site

    Lysaker, Norway

  • Pfizer Investigational Site

    Skedsmokorset, Norway

  • Pfizer Investigational Site

    Hønefoss, Buskerud, Norway

  • Pfizer Investigational Site

    Łask, Poland

  • Pfizer Investigational Site

    Lodz, Poland

  • Pfizer Investigational Site

    Lodz, Poland

  • Pfizer Investigational Site

    Lublin, Poland

  • Pfizer Investigational Site

    Warsaw, Poland

  • Pfizer Investigational Site

    A Coruña, Spain

  • Pfizer Investigational Site

    Huelva, Spain

  • Pfizer Investigational Site

    Málaga, Spain

  • Pfizer Investigational Site

    Valencia, Spain

Showing 40 of 62 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.